ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total value of $928,000.00. Following the completion of the sale, the insider now owns 1,647,447 shares in the company, valued at $15,288,308.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Sarina Tanimoto also recently made the following trade(s):
- On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total value of $21,133.86.
- On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total value of $3,996.00.
- On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total value of $890,977.56.
- On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total value of $6,307.00.
ARS Pharmaceuticals Stock Performance
Shares of NASDAQ SPRY opened at $9.06 on Thursday. The stock's fifty day simple moving average is $8.69 and its 200 day simple moving average is $6.23. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $11.27.
#1 election stock
From Porter & Company | Ad
I’ve found the number one company to buy…
Before either Trump or Biden wins in November.
It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power.
For the full story, click here.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.07. Analysts predict that ARS Pharmaceuticals, Inc. will post -0.69 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on SPRY shares. Wedbush reiterated an "outperform" rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. SVB Leerink upgraded ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $6.00 to $18.00 in a research report on Tuesday, March 5th. William Blair upgraded ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research report on Tuesday, February 20th. Finally, Leerink Partnrs upgraded ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 5th.
Check Out Our Latest Stock Analysis on SPRY
Hedge Funds Weigh In On ARS Pharmaceuticals
A number of hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter worth $632,000. Barclays PLC boosted its position in shares of ARS Pharmaceuticals by 127.1% in the fourth quarter. Barclays PLC now owns 40,374 shares of the company's stock worth $222,000 after buying an additional 22,597 shares during the period. Nantahala Capital Management LLC boosted its position in shares of ARS Pharmaceuticals by 45.3% in the fourth quarter. Nantahala Capital Management LLC now owns 1,596,504 shares of the company's stock worth $8,749,000 after buying an additional 497,429 shares during the period. Creative Planning boosted its position in shares of ARS Pharmaceuticals by 11.7% in the fourth quarter. Creative Planning now owns 31,201 shares of the company's stock worth $171,000 after buying an additional 3,270 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $423,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
